Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.54 Insider Own79.53% Shs Outstand5.88M Perf Week-15.22%
Market Cap6.75M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.18M Perf Month-10.00%
Income-8.98M PEG- EPS next Q-0.29 Inst Own9.90% Short Float0.47% Perf Quarter-35.71%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio0.30 Perf Half Y-
Book/sh0.20 P/B5.97 EPS next Y- ROA-440.01% Short Interest0.01M Perf Year-
Cash/sh0.65 P/C1.79 EPS next 5Y- ROE- 52W Range1.06 - 6.00 Perf YTD-75.63%
Dividend Est.- P/FCF- EPS past 5Y- ROI-794.30% 52W High-80.50% Beta-
Dividend TTM- Quick Ratio1.39 Sales past 5Y-33.33% Gross Margin- 52W Low10.38% ATR (14)0.15
Dividend Ex-Date- Current Ratio1.39 EPS Y/Y TTM-242.73% Oper. Margin0.00% RSI (14)43.19 Volatility12.06% 9.96%
Employees8 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price8.50
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-165.10% Payout- Rel Volume1.31 Prev Close1.19
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMay 29 Avg Volume18.60K Price1.17
SMA20-9.50% SMA50-21.55% SMA200-45.44% Trades Volume24,142 Change-1.68%
Chromocell Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. The company was founded on March 19, 2021 and is headquartered in Freehold, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Davis Todd CDirectorFeb 21 '24Option Exercise4.8029,167140,00229,167Feb 23 05:15 PM
Friedberg Ezra MDirectorFeb 21 '24Option Exercise4.8020,64199,077520,719Feb 23 05:12 PM